The Effect of Zoledronate on the Prevention of Pneumonia in Hip Fracture Patients
Status:
Recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
Nitrogen-containing bisphosphonates (N-BPs; such as alendronate and zoledronate) are commonly
used in the treatment of osteoporosis and fracture prevention, in which zoledronate has a
proven better efficacy than alendronate. In 2018, our real-world propensity score matched
study showed that the use of N-BPs was significantly associated with reduced risk of
myocardial infarction and stroke in hip fracture patients. In addition to cardiovascular
diseases, both preclinical study and sensitivity analysis also suggest evidence for N-BPs in
pneumonia prevention. Moreover, a pragmatic clinical trial is developed to evaluate effect of
the tested intervention in real-life routine clinical practice since traditional explanatory
radomised controlled trial (RCT) may have poor generalizability due to highly selected
patients and controlled environments. This study aims to evaluate if zoledronate reduces risk
of pneumonia in hip fracture patients using pragmatic clinical trial approach.
This is an open-label, multi-centre, pragmatic, randomised controlled trial. Patients will be
recruited from 4 hospitals, namely Caritas Medical Centre, Prince of Wales Hospital, Queen
Mary Hospital, and United Christian Hospital. Age, sex, body mass index, eGFR, history of
fracture, chronic respiratory diseases, and other medical history, will be measured and
recorded at recruitment.
Phase:
Phase 4
Details
Lead Sponsor:
The University of Hong Kong
Collaborators:
Caritas Medical Centre, Hong Kong Prince of Wales Hospital, Shatin, Hong Kong Queen Mary Hospital, Hong Kong United Christian Hospital